145 related articles for article (PubMed ID: 38090479)
1. Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
He J; Zou R; Kang L; Yu L; Wang P; Shao Y; Liang J; Wu D; Jin Z; Qu C
Front Oncol; 2023; 13():1283194. PubMed ID: 38090479
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
[TBL] [Abstract][Full Text] [Related]
3. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
5. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
[No Abstract] [Full Text] [Related]
6. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
7. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
Tu S; Zhou X; Guo Z; Huang R; Yue C; He Y; Li M; Chen Y; Liu Y; Chang LJ; Li Y
Front Oncol; 2019; 9():1350. PubMed ID: 31867275
[No Abstract] [Full Text] [Related]
8. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
9. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
10. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
14. Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report.
Wang K; Prabhu AV; Sasapu A; Lewis GD
Anticancer Res; 2021 Jul; 41(7):3635-3638. PubMed ID: 34230160
[TBL] [Abstract][Full Text] [Related]
15. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
16. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Feng G; Li Q; Zhu H; Jiang Y; Yuan J; Fu Y; Deng Q
Front Oncol; 2021; 11():726134. PubMed ID: 34604065
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
